Liang-I Kang

Ms. Liang-I Kang


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
EWEmma S. Winkler
Emma S. Winkler
ABAdam L. Bailey
Adam L. Bailey
NKNatasha M. Kafai
Natasha M. Kafai
SNSharmila Nair
Sharmila Nair
BMBroc T. McCune
Broc T. McCune
MDMichael Diamond
Michael Diamond

24 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CNCallie A. Norris
Callie A. Norris
MHMu He
Mu He
LKLiang-I Kang
Liang-I Kang
MDMichael Qi Ding
Michael Qi Ding
JRJosiah E. Radder
Josiah E. Radder
WMWendy M. Mars
Wendy M. Mars
Exogenous interleukin 6 (IL-6), synthesized at the initiation of the acute phase response, is considered responsible for signaling hepatocytes to produce acute phase proteins. It is widely posited that IL-6 is either delivered to the liver in an endocrine fashion from immune cells at the site of injury, or alternatively, in a paracrine manner by hepatic immune cells within the liver. A recent publication showed there was a muted IL-6 response in lipopolysaccharide (LPS)-injured mice when nuclear NFκB was specifically inactivated in the hepatocytes. This indicates hepatocellular signaling is also involved in regulating the acute phase production of IL-6. Herein, we present extensive in vitro and in vivo evidence that normal hepatocytes are directly induced to synthesize IL-6 mRNAs and protein by challenge with LPS, a bacterial hepatotoxin, and by HGF, an important regulator of hepatic homeostasis. As the IL-6 receptor is found on the hepatocyte, these results reveal that induction of the acute phase response can be regulated in an autocrine as well as endocrine/paracrine fashion. Further, herein we provide data indicating that following partial hepatectomy (PHx), HGF differentially regulates IL-6 production in hepatocytes (induces) versus immune cells (suppresses), signifying disparate regulation of the cell sources involved in IL-6 production is a biologically relevant mechanism that has previously been overlooked. These findings have wide ranging ramifications regarding how we currently interpret a variety of in vivo and in vitro biological models involving elements of IL-6 signaling and the hepatic acute phase response.

13 December 2012 in Cells
Verified
Journal Article
Open access
PDF file
LKLiang-I Kang
Liang-I Kang
WMWendy M. Mars
Wendy M. Mars
GMGeorge K. Michalopoulos
George K. Michalopoulos
Liver regeneration is a complex phenomenon aimed at maintaining a constant liver mass in the event of injury resulting in loss of hepatic parenchyma. Partial hepatectomy is followed by a series of events involving multiple signaling pathways controlled by mitogenic growth factors (HGF, EGF) and their receptors (MET and EGFR). In addition multiple cytokines and other signaling molecules contribute to the orchestration of a signal which drives hepatocytes into DNA synthesis. The other cell types of the liver receive and transmit to hepatocytes complex signals so that, in the end of the regenerative process, complete hepatic tissue is assembled and regeneration is terminated at the proper time and at the right liver size. If hepatocytes fail to participate in this process, the biliary compartment is mobilized to generate populations of progenitor cells which transdifferentiate into hepatocytes and restore liver size.

26 April 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
JBJad I. Belle
Jad I. Belle
DSDevashish Sen
Devashish Sen
JBJohn M. Baer
John M. Baer
XLXiuting Liu
Xiuting Liu
VKVarintra Krisnawan
Varintra Krisnawan
DDDavid DeNardo
David DeNardo
Pancreatic ductal adenocarcinoma (PDAC) therapeutic resistance is largely attributed to a unique tumor microenvironment embedded with an abundance of cancer-associated fibroblasts (CAF). Distinct CAF populations were recently identified, but the phenotypic drivers and specific impact of CAF heterogeneity remain unclear. In this study, we identify a subpopulation of senescent myofibroblastic CAFs (SenCAF) in mouse and human PDAC. These SenCAFs are a phenotypically distinct subset of myofibroblastic CAFs that localize near tumor ducts and accumulate with PDAC progression. To assess the impact of endogenous SenCAFs in PDAC, we used an LSL-KRASG12D;p53flox;p48-CRE;INK-ATTAC (KPPC-IA) mouse model of spontaneous PDAC with inducible senescent cell depletion. Depletion of senescent stromal cells in genetic and pharmacologic PDAC models relieved immune suppression by macrophages, delayed tumor progression, and increased responsiveness to chemotherapy. Collectively, our findings demonstrate that SenCAFs promote PDAC progression and immune cell dysfunction. Significance: CAF heterogeneity in PDAC remains poorly understood. In this study, we identify a novel subpopulation of senescent CAFs that promotes PDAC progression and immunosuppression. Targeting CAF senescence in combination therapies could increase tumor vulnerability to chemo or immunotherapy. See related article by Ye et al., p. 1302.

27 September 2022 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
VKVarintra Krisnawan
Varintra Krisnawan
JBJad I. Belle
Jad I. Belle
NKNatalie L. Kingston
Natalie L. Kingston
JHJohn M. Herndon
John M. Herndon
GHGraham D. Hogg
Graham D. Hogg
DDDavid DeNardo
David DeNardo
The effects of radiotherapy (RT) on tumor immunity in pancreatic ductal adenocarcinoma (PDAC) are not well understood. To better understand if RT can prime antigen-specific T-cell responses, we analyzed human PDAC tissues and mouse models. In both settings, there was little evidence of RT-induced T-cell priming. Using in vitro systems, we found that tumor–stromal components, including fibroblasts and collagen, cooperate to blunt RT efficacy and impair RT-induced interferon signaling. Focal adhesion kinase (FAK) inhibition rescued RT efficacy in vitro and in vivo, leading to tumor regression, T-cell priming, and enhanced long-term survival in PDAC mouse models. Based on these data, we initiated a clinical trial of defactinib in combination with stereotactic body RT in patients with PDAC (NCT04331041). Analysis of PDAC tissues from these patients showed stromal reprogramming mirroring our findings in genetically engineered mouse models. Finally, the addition of checkpoint immunotherapy to RT and FAK inhibition in animal models led to complete tumor regression and long-term survival. Significance: Checkpoint immunotherapeutics have not been effective in PDAC, even when combined with RT. One possible explanation is that RT fails to prime T-cell responses in PDAC. Here, we show that FAK inhibition allows RT to prime tumor immunity and unlock responsiveness to checkpoint immunotherapy. This article is highlighted in the In This Issue feature, p. 2711

10 August 2023 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JBJohn M. Baer
John M. Baer
CZChong Zuo
Chong Zuo
LKLiang-I Kang
Liang-I Kang
ALAngela Alarcon de la Lastra
Angela Alarcon de la Lastra
NBNicholas C. Borcherding
Nicholas C. Borcherding
DDDavid DeNardo
David DeNardo